Information Provided By: 
Fly News Breaks for January 6, 2020
PFE
Jan 6, 2020 | 16:33 EDT
RBC Capital analyst Randall Stanicky initiated coverage of Pfizer with an Outperform rating and $46 price target, calling the stock his top large cap idea in the pharmaceutical sector. He likes the company's best-in-class growth on its newly "shrunk" biopharma base following its strategic actions for its Consumer and Upjohn units, noted Stanicky. He also sees upside for Vyndaqel and Ibrance and thinks the company has five years to deploy capital to further bolster its pipeline before its loss-of-exclusivity risk in 2026, the analyst added.
News For PFE From the Last 2 Days
PFE
Apr 25, 2024 | 10:25 EDT
Bullish option flow detected in Pfizer with 50,393 calls trading, 2x expected, and implied vol increasing over 2 points to 28.83%. Sep-24 27.5 calls and Mar-25 42.5 calls are the most active options, with total volume in those strikes near 27,600 contracts. The Put/Call Ratio is 0.21. Earnings are expected on May 1st.
